April 24, 2018 / 10:41 AM / 3 months ago

BRIEF-MediciNova Announces Presentation Of SPRINT-MS Phase 2b Trial Of MN-166 (Ibudilast)

April 24 (Reuters) - MediciNova Inc:

* MEDICINOVA ANNOUNCES THE PRESENTATION OF THE SPRINT-MS PHASE 2B TRIAL OF MN-166 (IBUDILAST) IN PROGRESSIVE MS AT THE AMERICAN ACADEMY OF NEUROLOGY (AAN) 70TH ANNUAL MEETING PLENARY SESSION WITH ADDITIONAL IMAGING DATA

* MEDICINOVA - FOR PRIMARY ENDPOINT, MN-166 DEMONSTRATED STATISTICALLY SIGNIFICANT 48% REDUCTION IN PROGRESSION OF WHOLE BRAIN ATROPHY VERSUS PLACEBO IN MODIFIED ITT POPULATION

* MEDICINOVA - FOR SECONDARY ENDPOINT OF CORTICAL ATROPHY , MN-166 SHOWED A STATISTICALLY SIGNIFICANT 80% REDUCTION IN PROGRESSION OF CORTICAL ATROPHY

* MEDICINOVA- FOR SECONDARY ENDPOINT OF RETINAL NERVE FIBER LAYER THICKNESS, MN-166 HAD NO EFFECT ON PROGRESSION OF RETINAL NERVE FIBER LAYER THINNING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below